2021
DOI: 10.1016/j.urolonc.2020.12.003
|View full text |Cite
|
Sign up to set email alerts
|

“Future role of [18F]-FDG PET/CT in patients with bladder cancer in the new era of neoadjuvant immunotherapy?”

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 35 publications
0
1
0
Order By: Relevance
“…In the context of immunotherapy, Marandino et al recently reported that [ 18 F]-FDG PET/CT would have prevented 7% of patients with non-enlarged lymph nodes (<8 mm) from inappropriately receiving neoadjuvant pembrolizumab. 11,12 Some results support the idea that interpretation criteria in [ 18 F]-FDG PET/CT should be adjusted according to the size of the nodes. 13 While a mild uptake can lead to classifying enlarged lymph nodes as cN+, strong uptake should be required for small ones to avoid false positives.…”
mentioning
confidence: 99%
“…In the context of immunotherapy, Marandino et al recently reported that [ 18 F]-FDG PET/CT would have prevented 7% of patients with non-enlarged lymph nodes (<8 mm) from inappropriately receiving neoadjuvant pembrolizumab. 11,12 Some results support the idea that interpretation criteria in [ 18 F]-FDG PET/CT should be adjusted according to the size of the nodes. 13 While a mild uptake can lead to classifying enlarged lymph nodes as cN+, strong uptake should be required for small ones to avoid false positives.…”
mentioning
confidence: 99%